Royce & Associates Bought These Three Stocks

Page 2 of 2

Royce had increased its holdings of Hi-Tech Pharmacal Co. (NASDAQ:HITK) by 62% between July and September to about 860,000 shares; the fund now owns 1.3 million shares of the company, giving it about 10% of the total shares outstanding. Billionaire Israel Englander’s Millennium Management increased its own stake in the company to about 130,000 shares at the end of September (find more stocks that Englander liked). The $460 million market cap Hi Tech (again, there seems to be over $3 million in average daily dollar volume) just announced better-than-expected quarterly results, as earnings declined by less than had been expected. The trailing and forward P/E multiples are now 12, which might be considered a good price if the company can stop the decline in its business. Hi Tech can be compared to Mylan Inc. (NASDAQ:MYL), which is considerably larger and has been reporting strong growth numbers. While it is priced at a premium relative to Hi Tech- Mylan’s trailing P/E is 19- its superior size and performance might justify that valuation.

DTS Inc. (NASDAQ:DTS) was another Royce buy, with the fund’s position increasing to 1.7 million shares from 1.2 million at the beginning of October. The audio processing technology has a smaller market capitalization than the other two companies we’ve discussed, at about $290 million, but again seems to have over $1 million in average daily solar volume. Renaissance Technologies, whose founder Jim Simons is now a billionaire, owned about 300,000 shares according to its most recent 13F filing. See Renaissance Technologies’ top stock picks. DTS reported a large loss last quarter but revenue was up and analyst estimates have the stock trading at 14 times consensus earnings for 2013. However, the most recent data shows that about 18% of the outstanding shares are held short and so we’d conclude that a number of market players are bearish on the company. Dolby Laboratories, Inc. (NYSE:DLB) is also widely shorted, and its P/Es are in the 14-15 range, but that company experienced a decline in revenue as well as earnings last quarter compared to the same period in the previous year. It’s possible that DTS is a better buy, but we’d need to research the company further.

Page 2 of 2